Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1991 Jul;64(1):144–148. doi: 10.1038/bjc.1991.258

The antileukaemic activity of 5-Aza-2 deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia.

D J Richel 1, L P Colly 1, J C Kluin-Nelemans 1, R Willemze 1
PMCID: PMC1977302  PMID: 1713050

Abstract

In the present study we demonstrate that Aza-dC in combination with Amsacrine has major antileukaemic properties in patients who have not already received extensive Ara-C therapy. Eight out of 11 patients in their first relapse of acute leukaemia achieved complete remission. Cross resistance between Ara-C and Aza-dC was revealed by the lack of antileukaemic activity in five patients with with Ara-C resistant leukaemia. Combination therapy with Aza-dC/Ams-acrine induced a considerable period of a granulocytopenia (28-35 days), while the toxic effect on erythro- and megakaryopoiesis was comparable to that reported for high dose Ara-C/Amsacrine chemotherapy. Remarkable is the long disappearance time for leukaemic blast cells in bone marrow, i.e. 3-5 weeks in some cases. Analysis of cell membrane markers showed a loss of the early differentiation antigens CD34 and CD33 from leukaemic bone marrow cells after 7 days of Aza-dC treatment, which is suggestive of leukaemic cell differentiation. In the small group of patients tested for DNA hypomethylation no association existed between the degree of hypomethylation and clinical response. Non-haematologic side effects were considerable in patients receiving the highest dosages of Aza-dC and consisted of severe, although usually reversible, gastrointestinal and neurological complications. In comparison with Ara-C, Aza-dC causes less nausea and vomiting and is therefore better tolerated.

Full text

PDF
144

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bouchard J., Momparler R. L. Incorporation of 5-Aza-2'-deoxycytidine-5'-triphosphate into DNA. Interactions with mammalian DNA polymerase alpha and DNA methylase. Mol Pharmacol. 1983 Jul;24(1):109–114. [PubMed] [Google Scholar]
  2. Creusot F., Acs G., Christman J. K. Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine. J Biol Chem. 1982 Feb 25;257(4):2041–2048. [PubMed] [Google Scholar]
  3. Davis R. W., Thomas M., Cameron J., St John T. P., Scherer S., Padgett R. A. Rapid DNA isolations for enzymatic and hybridization analysis. Methods Enzymol. 1980;65(1):404–411. doi: 10.1016/s0076-6879(80)65051-4. [DOI] [PubMed] [Google Scholar]
  4. Ley T. J., DeSimone J., Anagnou N. P., Keller G. H., Humphries R. K., Turner P. H., Young N. S., Keller P., Nienhuis A. W. 5-azacytidine selectively increases gamma-globin synthesis in a patient with beta+ thalassemia. N Engl J Med. 1982 Dec 9;307(24):1469–1475. doi: 10.1056/NEJM198212093072401. [DOI] [PubMed] [Google Scholar]
  5. Lin K. T., Momparler R. L., Rivard G. E. Sample preparation for the determination of 5-aza-2'-deoxycytidine in plasma by high-performance liquid chromatography. J Chromatogr. 1985 Nov 29;345(1):162–167. doi: 10.1016/0378-4347(85)80148-1. [DOI] [PubMed] [Google Scholar]
  6. Momparier R. L., Gonzales F. A. Effect of intravenous infusion of 5-aza-2'-deoxycytidine on survival time of mice with L1210 leukemia. Cancer Res. 1978 Sep;38(9):2673–2678. [PubMed] [Google Scholar]
  7. Momparler R. L., Rivard G. E., Gyger M. Clinical trial on 5-aza-2'-deoxycytidine in patients with acute leukemia. Pharmacol Ther. 1985;30(3):277–286. doi: 10.1016/0163-7258(85)90052-x. [DOI] [PubMed] [Google Scholar]
  8. Pallesen G., Plesner T. The third international workshop and conference on human leukocyte differentiation antigens with an up-to-date overview of the CD nomenclature. Leukemia. 1987 Mar;1(3):231–234. [PubMed] [Google Scholar]
  9. Peters W. G., Willemze R., Colly L. P. Results of induction and consolidation treatment with intermediate and high-dose cytosine arabinoside and m-Amsa of patients with poor-risk acute myelogenous leukaemia. Eur J Haematol. 1988 Mar;40(3):198–204. doi: 10.1111/j.1600-0609.1988.tb00824.x. [DOI] [PubMed] [Google Scholar]
  10. Richel D. J., Colly L. P., Lurvink E., Willemze R. Comparison of the antileukaemic activity of 5 aza-2-deoxycytidine and arabinofuranosyl-cytosine in rats with myelocytic leukaemia. Br J Cancer. 1988 Dec;58(6):730–733. doi: 10.1038/bjc.1988.298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Veselý J., Cihák A. Incorporation of a potent antileukemic agent, 5-aza-2'-deoxycytidine, into DNA of cells from leukemic mice. Cancer Res. 1977 Oct;37(10):3684–3689. [PubMed] [Google Scholar]
  12. Wilson V. L., Jones P. A., Momparler R. L. Inhibition of DNA methylation in L1210 leukemic cells by 5-aza-2'-deoxycytidine as a possible mechanism of chemotherapeutic action. Cancer Res. 1983 Aug;43(8):3493–3496. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES